Trivarx Ltd Net Assets
Trivarx Ltd net assets. Based on the latest financial reports, Trivarx Ltd (TRI) has net assets worth AU$15.97 Million AUD (≈ $11.30 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$16.53 Million ≈ $11.70 Million USD) and total liabilities (AU$565.64K ≈ $400.22K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore TRI net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$15.97 Million |
| % of Total Assets | 96.58% |
| Annual Growth Rate | 3.96% |
| 5-Year Change | 124.73% |
| 10-Year Change | 19.94% |
| Growth Volatility | 70.38 |
Net Assets of Trivarx Ltd (2001–2026)
Net assets of Trivarx Ltd from 2001 to 2026. This chart illustrates how Trivarx Ltd's net assets have evolved over time, based on quarterly financial data. See Trivarx Ltd balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Trivarx Ltd (2001–2026)
The table below shows the annual net assets of Trivarx Ltd from 2001 to 2026. For live market cap and overall valuation, see TRI market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2026-06-30 | AU$15.97 Million ≈ $11.30 Million |
+26.21% |
| 2025-06-30 | AU$12.65 Million ≈ $8.95 Million |
+31.47% |
| 2024-06-30 | AU$9.62 Million ≈ $6.81 Million |
+57.00% |
| 2023-06-30 | AU$6.13 Million ≈ $4.34 Million |
-13.74% |
| 2022-06-30 | AU$7.11 Million ≈ $5.03 Million |
-56.71% |
| 2021-06-30 | AU$16.42 Million ≈ $11.62 Million |
+30.19% |
| 2020-06-30 | AU$12.61 Million ≈ $8.92 Million |
+46.54% |
| 2019-06-30 | AU$8.60 Million ≈ $6.09 Million |
-38.48% |
| 2018-06-30 | AU$13.99 Million ≈ $9.90 Million |
+5.05% |
| 2017-06-30 | AU$13.31 Million ≈ $9.42 Million |
+56.74% |
| 2016-06-30 | AU$8.49 Million ≈ $6.01 Million |
-6.77% |
| 2015-06-30 | AU$9.11 Million ≈ $6.45 Million |
+236.17% |
| 2014-06-30 | AU$2.71 Million ≈ $1.92 Million |
+6.78% |
| 2013-06-30 | AU$2.54 Million ≈ $1.80 Million |
+3.84% |
| 2012-06-30 | AU$2.44 Million ≈ $1.73 Million |
+107.58% |
| 2011-06-30 | AU$1.18 Million ≈ $833.18K |
+7.29% |
| 2010-06-30 | AU$1.10 Million ≈ $776.59K |
-55.41% |
| 2009-06-30 | AU$2.46 Million ≈ $1.74 Million |
-56.63% |
| 2008-06-30 | AU$5.68 Million ≈ $4.02 Million |
+201.61% |
| 2007-06-30 | AU$1.88 Million ≈ $1.33 Million |
-16.68% |
| 2006-06-30 | AU$2.26 Million ≈ $1.60 Million |
-49.09% |
| 2005-06-30 | AU$4.44 Million ≈ $3.14 Million |
-8.67% |
| 2004-06-30 | AU$4.86 Million ≈ $3.44 Million |
-5.68% |
| 2003-06-30 | AU$5.15 Million ≈ $3.64 Million |
-14.89% |
| 2002-06-30 | AU$6.05 Million ≈ $4.28 Million |
+0.06% |
| 2001-06-30 | AU$6.05 Million ≈ $4.28 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Trivarx Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11087171000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Trivarx Ltd Net Assets Breakdown (June 2026)
Trivarx Ltd net assets breakdown by equity component as of June 2026.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$113.73 Million | 712.17% |
| Other Comprehensive Income | AU$14.92 Million | 93.41% |
| Total Equity | AU$15.97 Million | 100.00% |
Trivarx Ltd Competitors by Market Cap
The table below lists competitors of Trivarx Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Godolphin Resources Ltd
AU:GRL
|
$8.99 Million |
|
Target Healthcare REIT Ltd
LSE:THRL
|
$9.00 Million |
|
Osmosun SA
PA:ALWTR
|
$9.00 Million |
|
Bermas SA
RO:BRM
|
$9.01 Million |
|
Avon Protection PLC
LSE:AVON
|
$8.98 Million |
|
Bolt Biotherapeutics
NASDAQ:BOLT
|
$8.97 Million |
|
Kesla Oyj A
HE:KELAS
|
$8.97 Million |
|
Asmallworld AG
SW:ASWN
|
$8.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Trivarx Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 12,652,377 to 15,969,118, a change of 3,316,741 (26.2%).
- Net loss of 8,762,643 reduced equity.
- Other comprehensive income increased equity by 8,312,139.
- Other factors increased equity by 3,767,245.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-8.76 Million | -54.87% |
| Other Comprehensive Income | AU$8.31 Million | +52.05% |
| Other Changes | AU$3.77 Million | +23.59% |
| Total Change | AU$- | 26.21% |
Book Value vs Market Value Analysis
This analysis compares Trivarx Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-06-30 | AU$9.54 | AU$0.01 | x |
| 2002-06-30 | AU$5.57 | AU$0.01 | x |
| 2003-06-30 | AU$3.41 | AU$0.01 | x |
| 2004-06-30 | AU$2.52 | AU$0.01 | x |
| 2005-06-30 | AU$2.05 | AU$0.01 | x |
| 2006-06-30 | AU$0.75 | AU$0.01 | x |
| 2007-06-30 | AU$0.48 | AU$0.01 | x |
| 2008-06-30 | AU$0.95 | AU$0.01 | x |
| 2009-06-30 | AU$0.38 | AU$0.01 | x |
| 2010-06-30 | AU$0.16 | AU$0.01 | x |
| 2011-06-30 | AU$0.10 | AU$0.01 | x |
| 2012-06-30 | AU$0.12 | AU$0.01 | x |
| 2013-06-30 | AU$0.09 | AU$0.01 | x |
| 2014-06-30 | AU$0.08 | AU$0.01 | x |
| 2015-06-30 | AU$0.18 | AU$0.01 | x |
| 2016-06-30 | AU$0.08 | AU$0.01 | x |
| 2017-06-30 | AU$0.11 | AU$0.01 | x |
| 2018-06-30 | AU$0.07 | AU$0.01 | x |
| 2019-06-30 | AU$0.04 | AU$0.01 | x |
| 2020-06-30 | AU$0.01 | AU$0.01 | x |
| 2021-06-30 | AU$0.22 | AU$0.01 | x |
| 2022-06-30 | AU$0.07 | AU$0.01 | x |
| 2023-06-30 | AU$0.04 | AU$0.01 | x |
| 2024-06-30 | AU$0.03 | AU$0.01 | x |
| 2025-06-30 | AU$0.03 | AU$0.01 | x |
| 2026-06-30 | AU$1.74 | AU$0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Trivarx Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.04x
- Recent ROE (-54.87%) is above the historical average (-75.24%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 3.00% | 133.08% | 0.02x | 1.12x | AU$-436.18K |
| 2002 | 12.59% | 487.25% | 0.02x | 1.16x | AU$155.86K |
| 2003 | 1.55% | 138.52% | 0.01x | 1.06x | AU$-435.26K |
| 2005 | -41.21% | -1617.34% | 0.02x | 1.05x | AU$-2.27 Million |
| 2006 | -34.44% | -4533.35% | 0.01x | 1.08x | AU$-1.00 Million |
| 2007 | -75.98% | -17111.58% | 0.00x | 1.10x | AU$-1.62 Million |
| 2008 | -82.06% | -5117.77% | 0.01x | 1.09x | AU$-5.22 Million |
| 2009 | -123.33% | 0.00% | 0.00x | 1.11x | AU$-3.28 Million |
| 2010 | -300.80% | -226748.21% | 0.00x | 1.28x | AU$-3.41 Million |
| 2011 | -273.46% | -1095.12% | 0.09x | 2.78x | AU$-3.34 Million |
| 2012 | -136.11% | -6349.51% | 0.01x | 2.24x | AU$-3.57 Million |
| 2013 | -43.21% | -5703.14% | 0.00x | 2.13x | AU$-1.35 Million |
| 2014 | -15.80% | 0.00% | 0.00x | 1.86x | AU$-699.36K |
| 2015 | -86.95% | -3024.36% | 0.02x | 1.67x | AU$-8.83 Million |
| 2016 | -68.57% | -31483.09% | 0.00x | 2.11x | AU$-6.67 Million |
| 2017 | -73.49% | -42359.62% | 0.00x | 1.45x | AU$-11.12 Million |
| 2018 | -116.54% | -7956.14% | 0.01x | 1.36x | AU$-17.70 Million |
| 2019 | -76.55% | -1806.51% | 0.03x | 1.55x | AU$-7.45 Million |
| 2020 | -37.28% | -3521.24% | 0.01x | 1.11x | AU$-5.96 Million |
| 2021 | -9.06% | -1462.38% | 0.01x | 1.06x | AU$-3.13 Million |
| 2022 | -178.95% | -31759.35% | 0.00x | 1.19x | AU$-13.43 Million |
| 2023 | -49.55% | -14132.93% | 0.00x | 1.25x | AU$-3.75 Million |
| 2024 | -12.52% | -138.48% | 0.08x | 1.09x | AU$-2.23 Million |
| 2025 | -7.45% | -83.55% | 0.08x | 1.07x | AU$-2.21 Million |
| 2026 | -54.87% | 0.00% | 0.00x | 1.04x | AU$-10.36 Million |
Industry Comparison
This section compares Trivarx Ltd's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $9,032,992
- Average return on equity (ROE) among peers: -42.26%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Trivarx Ltd (TRI) | AU$15.97 Million | 3.00% | 0.04x | $8.98 Million |
| Adheris Health Limited (AHE) | $15.17 Million | -29.36% | 0.15x | $86.70 |
| Alcidion Group Ltd (ALC) | $3.75 Million | -7.43% | 0.00x | $104.52 Million |
| ARTRYA Ltd (AYA) | $40.64 Million | -42.21% | 0.08x | $350.26 Million |
| Beamtree Holdings Ltd (BMT) | $5.55 Million | 28.34% | 0.26x | $13.57 Million |
| Cogstate Ltd (CGS) | $6.74 Million | -13.43% | 0.25x | $370.56 Million |
| Careteq Ltd (CTQ) | $6.30 Million | -83.38% | 0.27x | $5.43 Million |
| Doctor Care Anywhere Group Plc (DOC) | $25.04 Million | -124.92% | 0.11x | $24.65 Million |
| Echoiq Ltd (EIQ) | $8.02 Million | -74.71% | 0.28x | $226.79 Million |
| Emyria Ltd (EMD) | $6.79 Million | -75.53% | 0.50x | $22.83 Million |
| Enlitic Inc (ENL) | $-27.66 Million | 0.00% | 0.00x | $7.50 Million |
About Trivarx Ltd
TrivarX Limited, a health technology company, engages in the development of AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. The company was formerly known as Med… Read more